Canada
Dr. Martin Gleave is a distinguished professor and chairman of the Department of Urologic Sciences at the University of British Columbia (UBC), and a British Columbia Leadership Chair. He is co-founder and director of the Vancouver Prostate Centre, now a UBC and national Centre of Excellence, publishing more than 650 papers with 60,000 citations, and attracting over $120M in research funding.
Dr. Gleave is a surgeon-scientist whose research characterizes molecular mechanisms mediating treatment resistance in cancer, and designing co-targeting strategies to improve cancer control. He has patented several anti-cancer drugs and founded OncoGenex Pharmaceuticals to develop OGX-011 and OGX-427, inhibitors of cytoprotective chaperones clusterin and Hsp27 which progressed to Phase III and Phase II trials world-wide. OncoGenex was awarded Canadian Biotech Company of the Year in 2010. Dr. Gleave also recently co-founded TRiADD and Sustained Therapeutics.
In 2017, Dr. Gleave was appointed to the Order of Canada for his leadership role in developing new treatments for prostate cancer and for his research on mechanisms mediating treatment resistance in cancer. In 2020, he was inducted as a fellow in the National Academy of Inventors.
Dr. Gleave is the recipient of numerous awards, including the 2018 Dr. Chew Wei Memorial Prize in Cancer Research, the Huggins Medal from the Society of Urologic Oncology, the Richard Williams Award from the American Urological Association, the Barringer Medal from the American Association of Genitourinary Surgeons; the Eugene Fuller Award from the American Urological Association; the Aubrey Tingle Prize from the Michael Smith Foundation for Health Research; and the NCIC William Rawls Award for contributions to cancer control in Canada. He was appointed a Distinguished University Scholar at UBC in 2003 and awarded a BC Leadership Chair in 2005, the 2006 BC Biotech Award for Innovation and Achievement, and the 2007 BC Innovation Council Frontiers in Research Award.
Canada
Dr. Tanguay is Professor and Chair of the Division of Urology at McGill University and holds the Mostafa Elhilali and David Azrieli Chair in urologic sciences. He is co-director
of the Urologic Oncology fellowship program at McGill University. Dr. Tanguay completed his residency training at McGill University and a fellowship in Urologic
Oncology at the University of Texas M. D. Anderson Cancer Center.
Dr. Tanguay served as a member of the executive committee of many Societies including the Quebec Urological Association, the Canadian Urological Association,
the Genito-Urinary group of the National Cancer Institute of Canada and the Société Internationale d’Urologie. He is a founding member of the Kidney Cancer Research
Network of Canada and the Canadian Kidney Cancer information system and continues to serve on the Steering committee of both organizations. He is currently the Chair of
the Medical Advisory board of Kidney Cancer Canada.
His research interests are on genomic profiling and clinical outcomes of Renal Cell Carcinoma. Dr. Tanguay has more than 200 publications and book chapters
and contributed to the development of a comprehensive kidney cancer research program within McGill University. Throughout his career he was actively involved in
medical education. He served on the scientific program committees and congress organization committees of different Societies. He was invited as a guest speaker
in over 30 different countries.
Dr. Tanguay served for over 10 years on the Board of Directors of the Société Internationale d’Urologie where he contributed to many of the changes leading to
the modernisation of the SIU and its activities. He served as the General Secretary of the SIU from 2011 to 2016 and as President from 2018-2019. He continues to serve
as the Treasurer of the Foundation of the Société Internationale d’Urologie
United States
Dr. Kurt McCammon serves as the Devine Chair in Genitourinary Reconstructive Surgery and chairman and professor of the Department of Urology at Eastern Virginia Medical School (EVMS). He is the program director of the Urology Residency Program and the Adult and Pediatric Genitourinary Reconstructive Surgery Fellowship Program at EVMS. He received his medical degree from the Medical College of Ohio and completed his urology residency at EVMS followed by a two-year fellowship in genitourinary reconstructive surgery at EVMS.
He is a past president of the Society of Genitourinary Reconstructive Surgeons and serves on the board of IVUmed and as the Mid-Atlantic Representative on the board of the AUA, and is a member of the American Urological Association, American College of Surgeons, IVUmed and SIU. Dr. McCammon is a Diplomate of the American Board of Urology.
IN 2006, Kurt became involved with IVU in his first trip to Jos, Nigeria. This experience changed his life and practice. Serving on more than 25 humanitarian trips to work with host urologists training in genitourinary reconstruction, he currently makes 4-6 humanitarian trips yearly to Africa, Central America, the Caribbean and Southeast Asia.
At his own institution, development and funding The Health Sciences Academy, an immersion program of exposure to health fields for underrepresented high school students has been a joy, which led to the development of a program for first generation underrepresented pre-med college students, providing experience and mentorship for success in medical school.
He is humbly honored to have received the Distinguished Alumnus Award from the University of Toledo in October 2011 and the Christina Manthos Mentoring Award from the Society of Women in Urology in 2017.
Dr. McCammon lectures both nationally and internationally on the topics of male and female reconstruction and has authored numerous chapters and publications on pelvic reconstruction. His clinical interests include female urology, pelvic reconstruction, urethral reconstruction, and male incontinence.
United States
Dr. Inderbir Gill is chairman and a distinguished professor of the Catherine and Joseph Aresty Department of Urology, and founding executive director of the USC Institute of Urology at the Keck School of Medicine, University of Southern California (USC). He holds the Shirley & Donald Skinner Chair in Urologic Cancer Surgery and is associate dean of clinical innovation at USC. Previously, he was chairman and professor in the department of urology at the Cleveland Clinic, where he was on faculty for 12 years.
Since his arrival in 2009, the USC Institute of Urology has grown in scientific stature, clinical volumes, financial productivity and philanthropic gifts. Dr. Gill has provided significant contributions to scientific literature, publishing approximately 800 papers with 36,000 citations, editing numerous textbooks, and sitting on several urologic journal editorial boards.
Dr. Gill is elected to the prestigious American Association of Genitourinary Surgeons and the Clinical Society of AAGUS. Honours that he has received include the Dr. B. C. Roy Award for Eminent Medical Person, awarded by the President of India; the St. Paul’s Medal of the British Association of Urological Surgeons; an honorary fellowship of the Royal College of Surgeons of England; and the USC Presidential Medallion. In 2014, Thomson Reuters listed him as one of “The World’s Most Influential Scientific Minds.” For the American Urological Association, he has been the Ramon Guiteras Lecturer, its chair of Global Initiatives, and has received its Presidential Distinguished Citation. Dr. Gill was president of the 24th World Congress of Endourology & SWL.
Dr. Gill’s primary academic focus is advanced robotic urologic oncologic surgery for cancers of the kidney, bladder and prostate. His aggregate team has one of the world’s largest overall robotic/laparoscopic experiences for urologic oncologic surgery with more than 15,000 cases performed in the United States. More recently, his interest has expanded to focal targeted therapy for prostate cancer and artificial intelligence. In 2021, the USC Institute of Urology started the first funded Urology AI Center of any urology department in the nation.
India
Dr. Ravindra B. Sabnis, MD, is professor, chair & head of the Urology Deptartment at Muljibhai Patel Urological Hospital (MPUH) in Nadiad, India. He has served regional and national urological societies in various capacities including executive member, general secretary, and chair of the board of education. He is currently president of the Urological Society of India (USI). He was member of the executive council of Urological Association of Asia, a fellowship and award committee member of the World Endometriosis society, and a member of SIU Academy.
Dr. Sabnis has more than 150 publications, 250 guest lectures at national and international conferences, more than 60 live surgery demonstrations in India and abroad, two books and 10 book chapters to his credit. He is a reviewer of many urological journals. He has received awards recognizing his reviewing expertise from both the SIUJ and the Journal of Endourology.
He is an accredited teacher for urology training and has been a guide and mentor for more than 100 urology students. He is on the panel of examiners and inspectors for India’s national board of examinations. Dr. Sabnis conducts various teaching activities and has been awarded a teacher travelling scholarship by USI. He was invited as visiting professor by Hamad Medical Corporation in Doha, Qatar, and by the B.P. Koirala Institute of Health Sciences in Dharan, Nepal, where he was instrumental in starting its M.Ch-urology training program.
Dr. Sabnis has also received the USI’s highest award, Urology Gold medal, for the west zone in 2017 and for the national association in 2019; the Endourological Social Services Award of the World Endourology Society in 2018; the Best Teacher award of the national board in 2019; the Secretary Commendation – Global Leadership award of the AUA in 2019; the Best Paper Award of the BJUI in 2013; Honorary FRCS by the Royal College of Glasgow in 2021; and the Ralf Clayman mentor award of the World Endourology Society in 2022.
China
As a world-renowned surgeon and researcher in the field of urology, Professor Zhangqun Ye has made significant contributions to urological education, research and clinical services. In 2000, Professor Ye was elected as director of the urologic department of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Since then, he has made tremendous efforts to boost the development of clinical skills and scientific research of urological department. With the foresight to invest in leading technologies in urology, Professor Ye has promoted the clinical application and generalization of a series of innovations, such as laparoscopic system for urological surgery, robot-assisted procedures, percutaneous nephrolithotomy, flexible ureteroscopy, and fluorescence in situ hybridization for bladder cancer.
Professor Ye founded the Institute of Urology of Tongji Hospital and the Hubei Institute of Urology in 2012 and 2014, respectively. With outstanding achievements in both clinical management and basic research in urology, Tongji Hospital became one of the most important leaders in urology of China. In an attempt to facilitate high-quality medical provision, Professor Ye developed feasible training programs for urologists from primary hospitals in Hubei province and central China. In recognition of his extensive and profound contributions, he was awarded the Wu Jieping Medical Award of Urology, the State Scientific and Technological Progress Award, and the World Chinese Urological Society Award.
Owing to his distinguished work in leadership, Professor Ye was elected as chairman of Chinese Urological Association from 2010 to 2013. In this role, he led institutional reform and established a series of study groups for each subdiscipline of urology. Under the leadership of Professor Ye, nationwide urologists were integrated and joined together with genuine collaboration, which facilitated a series of large sample, multicenter randomized controlled trials and epidemiological surveys. Substantial research findings were published in top journals such as European Urology, Journal of Urology, and Asian Journal of Urology, providing unique insights and perspectives of Chinese urologists.
Together with world-renowned scholars, he founded the International Alliance of Urolithiasis and the Marco Polo Association of Urology to promote cooperation with leading scholars and institutions. Professor Ye has also led the delegation of Chinese urologists to attend several international meetings. These opportunities for academic exchanges and project cooperation boosted international clinical trials and promoted the clinical skills of urologists from both China and the world.
Canada
Dr. Dean Elterman is an associate professor of urology at the University of Toronto, sub-specializing in functional urology.
Dr. Elterman has been involved with the SIU for many years, currently serving as Vice-Chair of the Innovators Committee, as Chair of the Lower Urinary Tract Dysfunction Sub-Committee, as the national delegate for Canada, and as Co-Chair of the local organizing committee for this year’s Congress.
Dr. Elterman’s career has consistently been hallmarked by innovation. Among his many firsts, he was the first in Canada, and North America, to use InterStim II, InterStim Micro, InterStim X and Axonics for sacral neuromodulation; and the first to use many new BPH technologies including Rezum, iTind, Aquablation, Optilume BPH, Zenflow, and Urocross. He is the first physician globally to be named as a Center of Excellence for Rezum, Greenlight Vaporization, and InterStim Sacral Neuromodulation. He remains amongst the highest volume SNM implanters globally and is consistently involved in numerous international clinical trials. He is the lead author of the Male LUTS/BPH guidelines for the Canadian Urological Association, and has helped create national online programs in prostate cancer rehabilitation and a BPH decision aid. He has now authored 158 peer reviewed publications and has become a sought-after speaker and teacher. Dr. Elterman has travelled to lecture and teach surgery around the world, and is intimately involved in the development of several new technologies for application in overactive bladder, urinary incontinence and benign prostatic obstruction.
Dr. Elterman attended McGill University for his Bachelor’s degree, then completed his medical degree followed by residency in urologic surgery at the University of Toronto. He became a fellow of the Royal College of Physicians and Surgeons of Canada in 2011. He has completed a two-year fellowship in Functional Urology at Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital/Weill Cornell Medical College in New York City. While there, he also completed his Master’s degree in clinical epidemiology and health services research. In 2013, Dr. Elterman returned to Canada to join the faculty of the Division of Urology at the University of Toronto. As an attending urologist at the University Health Network, where he has cultivated a clinical and research interest in voiding dysfunction including novel technologies for BPH, sacral neuromodulation, male incontinence, sexual dysfunction, and men’s health. He holds a number of roles including medical director of the Sexual Health Clinic at Princess Margaret Cancer Centre and fellowship director for functional urology at his hospital.
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Since 2019, Bristol Myers Squibb has supported SIU’s global educational initiatives in Uro-Oncology through several programmes via the SIU Annual Congresses and
the eLearning platform SIU Academy. The support of Bristol Myers Squibb has been instrumental in the development of the Bench-to-Bedside GU Cancers Triad Meeting
since its inception, bringing the latest advances in Uro-Oncology treatments to urologists worldwide.
